NASDAQ : GTBP
GT Biopharma, Inc. — Financial statements
Healthcare · Biotechnology · United States
Last price 5.6 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 10.10M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Financial statements
Income statement
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|---|
| Selling, General & Admin | 12.86M | 8.95M | 8.57M | 7.11M | 12.45M | 47.92M |
| Research & Development | 3.48M | 3.47M | 5.80M | 6.47M | 8.81M | 9.59M |
| Operating Expenses | 16.34M | 12.42M | 14.36M | 13.58M | 21.26M | 57.52M |
| Operating Income | -16.34M | -12.42M | -14.36M | -13.58M | -21.26M | -57.52M |
| Interest Expense | -254.00K | -127.00K | -213.00K | -8.00K | -718.00K | |
| Interest & Investment Income | 178.00K | 123.00K | 402.00K | 780.00K | 292.00K | 38.00K |
| Other Non Operating Income (Expenses) | 11.65M | -16.93M | 800.00K | 4.82M | 119.00K | 211.00K |
| EBT Excluding Unusual Items | -4.76M | -29.35M | -13.16M | -8.19M | -20.85M | -57.98M |
| Gain (Loss) on Sale of Investments | 48.00K | -30.00K | -29.00K | |||
| Other Unusual Items | 998.00K | 547.00K | ||||
| Pretax Income | -4.76M | -28.35M | -13.16M | -7.60M | -20.88M | -58.01M |
| Net Income | -4.76M | -28.35M | -13.16M | -7.60M | -20.88M | -58.01M |
| Preferred Dividends & Other Adjustments | 6.62M | 6.09M | ||||
| Net Income to Common | -11.38M | -34.45M | -13.16M | -7.60M | -20.88M | -58.01M |
| Shares Outstanding (Basic) | 860.85K | 220.53K | 75.89K | 53.91K | 42.49K | 37.54K |
| Shares Outstanding (Diluted) | 860.85K | 220.53K | 75.89K | 53.91K | 42.49K | 37.54K |
| EPS (Basic) | -13.22 | -156.21 | -173.42 | -140.92 | -491.49 | -1,545.32 |
| EPS (Diluted) | -13.22 | -156.21 | -173.42 | -140.92 | -491.49 | -1,545.32 |
| Free Cash Flow | -14.43M | -12.91M | -12.90M | -8.85M | -15.22M | -15.61M |
| Free Cash Flow Per Share | -16.76 | -58.56 | -170.02 | -164.20 | -358.12 | -415.70 |
| EBIT | -16.34M | -12.42M | -14.36M | -13.58M | -21.26M | -57.52M |
Balance sheet
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | 4.96M | 6.81M | 3.95M | 1.08M | 5.67M | 8.97M |
| Short-Term Investments | 12.89M | 10.84M | 23.01M | |||
| Cash & Short-Term Investments | 4.96M | 6.81M | 3.95M | 13.97M | 16.51M | 31.98M |
| Prepaid Expenses | 227.00K | 567.00K | 188.00K | 84.00K | 54.00K | 190.00K |
| Restricted Cash | 94.00K | 94.00K | 93.00K | |||
| Other Current Assets | 507.00K | 634.00K | ||||
| Total Current Assets | 5.79M | 8.11M | 4.23M | 14.06M | 16.56M | 32.17M |
| Property, Plant & Equipment | 53.00K | 165.00K | ||||
| Other Long-Term Assets | 9.00K | |||||
| Total Assets | 5.79M | 8.11M | 4.23M | 14.11M | 16.74M | 32.17M |
| Accounts Payable | 1.02M | 748.00K | 3.85M | 4.33M | 3.14M | 8.19M |
| Accrued Expenses | 1.20M | 1.56M | 1.80M | 1.20M | 1.67M | 1.90M |
| Short-Term Debt | 31.00K | |||||
| Current Portion of Leases | 58.00K | 110.00K | ||||
| Other Current Liabilities | 11.00K | 252.00K | 1.05M | 19.00K | 138.00K | |
| Total Current Liabilities | 2.22M | 2.32M | 5.90M | 6.63M | 4.94M | 10.26M |
| Long-Term Leases | 64.00K | |||||
| Total Liabilities | 2.22M | 2.32M | 5.90M | 6.63M | 5.00M | 10.26M |
| Common Stock | 45.00K | 26.00K | 2.00K | 1.00K | 33.00K | 32.00K |
| Additional Paid-In Capital | 734.95M | 729.66M | 693.55M | 689.54M | 686.17M | 674.35M |
| Retained Earnings | -731.43M | -723.90M | -695.23M | -682.07M | -674.47M | -653.58M |
| Comprehensive Income & Other | 1.11M | |||||
| Total Common Equity | 3.57M | 5.79M | -1.67M | 7.47M | 11.73M | 21.91M |
| Shareholders' Equity | 3.57M | 5.79M | -1.67M | 7.48M | 11.73M | 21.91M |
| Total Liabilities & Equity | 5.79M | 8.11M | 4.23M | 14.11M | 16.74M | 32.17M |
| Total Debt | 58.00K | 174.00K | 31.00K | |||
| Net Cash (Debt) | 4.96M | 6.81M | 3.95M | 13.91M | 16.33M | 31.95M |
| Net Cash Per Share | 5.76 | 30.88 | 52.06 | 258.10 | 384.41 | 851.02 |
| Filing Date Shares Outstanding | 1.80M | 1.26M | 89.37K | 55.23K | 49.08K | 42.83K |
| Total Common Shares Outstanding | 1.79M | 1.02M | 89.37K | 55.23K | 43.63K | 42.75K |
| Working Capital | 3.57M | 5.79M | -1.67M | 7.42M | 11.62M | 21.91M |
| Book Value Per Share | 2.00 | 5.66 | -18.70 | 135.36 | 268.92 | 512.50 |
| Tangible Book Value | 3.57M | 5.79M | -1.67M | 7.47M | 11.73M | 21.91M |
| Tangible Book Value Per Share | 2.00 | 5.66 | -18.70 | 135.36 | 268.92 | 512.50 |
Cash flow statement
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|---|
| Net Income | -4.76M | -28.35M | -13.16M | -7.60M | -20.88M | -58.01M |
| Loss (Gain) From Sale of Investments | -48.00K | 30.00K | 29.00K | |||
| Stock-Based Compensation | 517.00K | 432.00K | 230.00K | 2.20M | 7.65M | 33.93M |
| Other Operating Activities | -11.65M | 15.93M | -800.00K | -5.23M | -20.00K | 509.00K |
| Change in Accounts Payable | 237.00K | -1.30M | 937.00K | 1.96M | -2.03M | 7.08M |
| Change in Other Net Operating Assets | 1.23M | 377.00K | -109.00K | -137.00K | 41.00K | 863.00K |
| Operating Cash Flow | -14.43M | -12.91M | -12.90M | -8.85M | -15.22M | -15.61M |
| Investment in Securities | 12.89M | -2.01M | 12.14M | -23.04M | ||
| Investing Cash Flow | 12.89M | -2.01M | 12.14M | -23.04M | ||
| Short-Term Debt Issued | 1.21M | |||||
| Total Debt Issued | 1.21M | |||||
| Net Debt Issued (Repaid) | 1.21M | |||||
| Issuance of Common Stock | 5.02M | 5.50M | 2.98M | 6.27M | 41.11M | |
| Repurchase of Common Stock | -224.00K | |||||
| Preferred Dividends Paid | -229.00K | -229.00K | ||||
| Dividends Paid | -229.00K | -229.00K | ||||
| Financing Cash Flow | 14.16M | 15.78M | 2.98M | 6.27M | -224.00K | 42.32M |
| Net Cash Flow | -267.00K | 2.86M | 2.96M | -4.59M | -3.30M | 3.67M |
| Free Cash Flow | -14.43M | -12.91M | -12.90M | -8.85M | -15.22M | -15.61M |
| Free Cash Flow Per Share | -16.76 | -58.56 | -170.02 | -164.20 | -358.12 | -415.70 |
| Levered Free Cash Flow | -8.87M | -12.01M | -9.62M | -4.68M | -10.91M | -824.62K |
| Unlevered Free Cash Flow | -8.71M | -11.93M | -9.62M | -4.55M | -10.90M | -375.88K |
| Cash Interest Paid | 213.00K | |||||
| Change in Working Capital | 1.47M | -920.00K | 828.00K | 1.82M | -1.99M | 7.94M |
Ratios
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|---|
| Market Capitalization | 9.60M | 8.35M | 6.81M | 10.56M | 28.84M | 93.05M |
| Enterprise Value | 4.64M | 5.82M | 397.69K | -5.36M | 8.25M | 57.20M |
| Last Close Price | 5.32 | 19.63 | 76.25 | 191.25 | 664.28 | 2,287.50 |
| PB Ratio | 2.66 | 1.44 | -4.08 | 1.41 | 2.46 | 4.25 |
| P/TBV Ratio | 2.69 | 1.44 | 1.41 | 2.46 | 4.25 | |
| Debt / Equity Ratio | 0.01 | 0.01 | 0.00 | |||
| Net Debt / Equity Ratio | -1.39 | -1.18 | 2.37 | -1.86 | -1.39 | -1.46 |
| Net Debt / FCF Ratio | 0.34 | 0.53 | 0.31 | 1.57 | 1.07 | 2.05 |
| Quick Ratio | 2.23 | 2.94 | 0.67 | 2.11 | 3.34 | 3.12 |
| Current Ratio | 2.61 | 3.50 | 0.72 | 2.12 | 3.35 | 3.14 |
| Return on Equity (ROE) | -113.52% | -1,377.41% | -453.39% | -79.09% | -124.15% | |
| Return on Assets (ROA) | -158.16% | -125.85% | -97.89% | -55.02% | -54.33% | -190.04% |
| Return on Capital Employed (ROCE) | -457.70% | -214.70% | 860.10% | -181.60% | -180.20% | -262.50% |
| Earnings Yield | -248.49% | -339.51% | -193.14% | -71.93% | -72.42% | -62.35% |
| FCF Yield | -150.28% | -154.63% | -189.36% | -83.81% | -52.77% | -16.77% |
| Buyback Yield / Dilution | -795.21% | -190.57% | -40.78% | -26.87% | -13.19% |